News | PET Imaging | August 19, 2016

New PET Imaging Technique Could Improve Understanding of Depression, Drug Treatments

Japanese study uses PET tracer to non-invasively assess neuron proliferation in areas of the brain known to be particularly affected by depression

PET, depression, neurogenesis, brain imaging, RIKEN Center for Life Science Technology study

August 19, 2016 — A new non-invasive positron emission tomography (PET) technique can obtain images of neuron proliferation in an area of the brain known to be particularly affected by depression. Scientists from the RIKEN Center for Life Science Technology (CLST) in Japan used the technique to observe this process, known as neurogenesis, in the subventricular zone and subgranular zone of the hippocampal dentate gyrus.

These two areas are known to be neurogenic regions, where neural stem cells give rise to new neurons throughout our lives. Hippocampal neurogenesis is known to be associated with depression and the effect of antidepressive medication, but it is also involved in learning and memory, so scientists are keen to find techniques that can monitor cell proliferation in the region. However, the process of neurogenesis is very hard to monitor non-invasively. It is possible using magnetic resonance imaging (MRI), but with MRI the tracers do not move into the brain effectively and must be injected directly into the brain fluid, making is invasive and difficult to perform.

PET is another method that has been used. Previously, attempts have been made to use a molecule called [18F]FLT as a marker for cell proliferation in the brain in PET, but unfortunately the difference in signal strength between regions with and without cell growth was small. "We were not exactly sure why this was happening," said Tamura, "but surmised that it is because the body actively pumps the molecule out of the brain through the blood-brain barrier, using active transport mechanisms. This means that it is difficult for [18F]FLT to accumulate in the brain in sufficient concentrations to allow effective imaging."

To test whether this was the case, they tried injecting rats with a drug called probenecid, which is known to inhibit the active transport of molecules like [18F]FLT outside of the brain. They were happy to see that the strategy worked. They found clear signals of neurogenesis in the two areas of the adult brain, and these signals were significantly decreased in the hippocampal dentate gyrus of rats that had been treated with corticosterone to trigger depression. When the rats were treated with an anti-depressive selective serotonin reuptake inhibitor, the amount of cell proliferation was shown to increase, demonstrating that the drugs were countering the loss of neurogenesis caused by the corticosterone.

According to Yosky Kataoka, M.D., Ph.D., who led the research team, "This is a very interesting finding, because it has been a longtime dream to find a non-invasive test that can give objective evidence of depression and simultaneously show whether drugs are working in a given patient. We have shown that it is possible, at least in experimental animals, to use PET to show the presence of depression and the effectiveness of drugs. Since it is known that these same brain regions are involved in depression in the human brain, we would like to try this technique in the clinic and see whether it turns out to be effective in humans as well."

For more information: www.riken.jp/en

Related Content

GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Life Image and Mendel.ai Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and Mendel.ai announced a new strategic partnership that will facilitate the adoption and enhancement of...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MaxQ AI Receives FDA Clearance for Accipio Ix Intracranial Hemorrhage Platform
Technology | Artificial Intelligence | November 07, 2018
MaxQ AI announced that its Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...